In a breakthrough published on February 4, 2026, a research team at Tohoku University identified a previously unknown anatomical structure within human lymph nodes called the intranodal lympho-venous shunt (inLVS).
The discovery, detailed in The Journal of Pathology, challenges the long-held “one-way” model of the lymphatic system by revealing a direct bypass route where lymph fluid can flow from the lymph sinuses directly into the veins.
The Discovery: Intranodal Lympho-Venous Shunts
Led by Dr. Ariunbuyan Sukhbaatar and Professor Tetsuya Kodama, the team used high-resolution imaging, including microCT and iron nanoparticles, to map all 22 types of lymph nodes.
Traditional View: It was previously believed that lymph fluid followed a strictly linear path, eventually entering the bloodstream only at the subclavian vein.
The New Architecture: The inLVS acts as a localized “short circuit,” allowing immune cells, fluid, and potentially cancer cells to transition directly from the lymph node into the blood vessels.
Mechanism: This shunt explains how the body can rapidly decrease swelling (edema) and clarifies the mysterious pathways of distant cancer metastasis.
Medical and Research Implications
Experts suggest this discovery will trigger a paradigm shift in how we treat chronic conditions and deliver medicine.
| Field | Potential Impact |
| Oncology | Closing these shunts could block malignant cells from using them as “back doors” to reach the bloodstream and spread to distant organs. |
| Lymphedema | Adjusting shunt function may provide the first radical treatment for chronic swelling often seen after cancer surgeries. |
| Drug Delivery | The shunts offer a new target for Lymphatic Drug Delivery Systems (LDDS), allowing for more precise pharmaceutical targeting. |
| Immunology | Reshapes our understanding of how immune cells are transported during an active infection or response to a vaccine. |
